The U.S. Food and Drug Administration has approved a novel weight loss medication, orforglipron, marketed as Foundayo, which offers patients a new level of convenience. It is the first GLP-1 drug in a "small molecule" pill form that can be taken at any time of day without regard to food or water intake, removing a significant adherence barrier associated with other oral treatments.
Like other GLP-1 medications, Foundayo mimics a natural hormone that regulates appetite by slowing digestion and promoting fullness. Its distinction lies in its chemical structure, which allows it to be absorbed easily through the digestive system even after eating. This contrasts with the peptide-based Wegovy pill, which is a "large molecule" drug that must be taken on an empty stomach. "For many people, a daily pill with no timing rules will feel easier and more normal, which could help adherence," says Dr. Melanie Jay, a professor at NYU Grossman School of Medicine.
In clinical trials, the drug demonstrated significant efficacy. Participants on the highest dose lost an average of about 27 pounds, or 12.4 percent of their starting body weight, compared to just 2.2 pounds for those on a placebo. Beyond weight reduction, the treatment also led to meaningful improvements in cardiovascular risk factors, including waist size, cholesterol, triglyceride levels, and blood pressure.
Availability and Cost Considerations
The manufacturer, Lilly, announced that Foundayo is immediately available through its LillyDirect platform with a prescription, with broader availability at pharmacies and through telehealth providers to follow. For patients paying out-of-pocket, the lowest dose will start at $149. For those with insurance, costs will vary. Some Medicare Part D beneficiaries may access it for $50 per month starting in July 2026, while commercially insured patients could pay as little as $25 monthly with a manufacturer's discount card, though final copays depend on individual plan details.
The approval of Foundayo expands the toolbox for obesity treatment, giving patients more choice based on lifestyle and cost. While injected therapies may offer greater maximum weight loss, this pill provides a convenient, refrigeration-free option without meal-timing constraints. Doctors note that more study is needed to determine which patients benefit most from this specific therapy, but they welcome it as another important option. The growing array of effective GLP-1 drugs means more individuals can find a suitable path to achieving meaningful health improvements.